| |
Latest 10 SEC filings (by transaction date) for APLT within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Mar 18/24 | Mar 14/24 | Shendelman Shoshana | Direct Ownership | Common Stock | S - Open market or private sale | -318,573 | $5.39 |
Mar 18/24 | Mar 14/24 | Perfetti Riccardo | Direct Ownership | Common Stock | S - Open market or private sale | -110,804 | $5.39 |
Mar 18/24 | Mar 14/24 | Hansard Adam | Direct Ownership | Common Stock | S - Open market or private sale | -48,871 | $5.39 |
Mar 18/24 | Mar 14/24 | Funtleyder Leslie D. | Direct Ownership | Common Stock | S - Open market or private sale | -28,727 | $5.39 |
Mar 18/24 | Dec 28/23 | Chinoporos Constantine | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 300,000 | |
Dec 22/23 | Dec 21/23 | Shendelman Shoshana | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 440,000 | |
Dec 22/23 | Dec 21/23 | Shendelman Shoshana | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 1,100,000 | |
Dec 22/23 | Dec 21/23 | Perfetti Riccardo | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 450,000 | |
Dec 22/23 | Dec 21/23 | Hansard Adam | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 400,000 | |
Dec 5/23 | Dec 1/23 | Kanter Stacy J. | Direct Ownership | Common Stock | P - Open market or private purchase | 30,000 | $2.18 |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for APLT within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Mar 18/24 | Mar 14/24 | Shendelman Shoshana | Direct Ownership | Common Stock | S - Open market or private sale | -318,573 | $5.39 |
Mar 18/24 | Mar 14/24 | Perfetti Riccardo | Direct Ownership | Common Stock | S - Open market or private sale | -110,804 | $5.39 |
Mar 18/24 | Mar 14/24 | Hansard Adam | Direct Ownership | Common Stock | S - Open market or private sale | -48,871 | $5.39 |
Mar 18/24 | Mar 14/24 | Funtleyder Leslie D. | Direct Ownership | Common Stock | S - Open market or private sale | -28,727 | $5.39 |
Mar 18/24 | Dec 28/23 | Chinoporos Constantine | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 300,000 | |
Dec 22/23 | Dec 21/23 | Shendelman Shoshana | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 440,000 | |
Dec 22/23 | Dec 21/23 | Shendelman Shoshana | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 1,100,000 | |
Dec 22/23 | Dec 21/23 | Perfetti Riccardo | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 450,000 | |
Dec 22/23 | Dec 21/23 | Hansard Adam | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 400,000 | |
Dec 5/23 | Dec 1/23 | Kanter Stacy J. | Direct Ownership | Common Stock | P - Open market or private purchase | 30,000 | $2.18 |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Cerevel Therapeutics Hold (OQ:CERE) |
Neurocrine Biosciences (OQ:NBIX) |
Regeneron Pharmaceuticals (OQ:REGN) |